Novel methylated DNA markers accurately discriminate Lynch syndrome associated colorectal neoplasia

Veroushka Ballester, William R. Taylor, Seth W. Slettedahl, Douglas W. Mahoney, Tracy C. Yab, Frank A. Sinicrope, Clement R. Boland, Graham P. Lidgard, Marcia R. Cruz-Correa, Thomas C. Smyrk, Lisa A. Boardman, David A. Ahlquist, John B. Kisiel

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: Acquired molecular changes in Lynch syndrome (LS) colorectal tumors have been largely unstudied. We identified methylated DNA markers (MDMs) for discrimination of colorectal neoplasia in LS and determined if these MDMs were comparably discriminant in sporadic patients. Patients & methods: For LS discovery, we evaluated DNA from 53 colorectal case and control tissues using next generation sequencing. For validation, blinded methylation-specific PCR assays to the selected MDMs were performed on 197 cases and controls. Results: OPLAH was the most discriminant MDM with areas under the receiver operating characteristic curve ≥0.97 for colorectal neoplasia in LS and sporadic tissues. ALKBH5, was uniquely hypermethylated in LS neoplasms. Conclusion: Highly discriminant MDMs for colorectal neoplasia in LS were identified with potential use in screening and surveillance.

Original languageEnglish (US)
Pages (from-to)2173-2187
Number of pages15
JournalEpigenomics
Volume12
Issue number24
DOIs
StatePublished - Dec 2020

Keywords

  • DNA methylation
  • biomarkers
  • colorectal neoplasms
  • colorectal neoplasms
  • colorectal physiology
  • colorectal prevention and control
  • hereditary nonpolyposis

ASJC Scopus subject areas

  • Genetics
  • Cancer Research

Fingerprint Dive into the research topics of 'Novel methylated DNA markers accurately discriminate Lynch syndrome associated colorectal neoplasia'. Together they form a unique fingerprint.

Cite this